BTIM Corp. Takes Position in Boston Scientific Corporation (BSX)

BTIM Corp. purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 12,002 shares of the medical equipment provider’s stock, valued at approximately $333,000.

Several other large investors have also recently made changes to their positions in the stock. State of Alaska Department of Revenue purchased a new stake in shares of Boston Scientific Corporation during the first quarter valued at about $241,000. Quantitative Systematic Strategies LLC raised its stake in shares of Boston Scientific Corporation by 29.0% in the first quarter. Quantitative Systematic Strategies LLC now owns 107,745 shares of the medical equipment provider’s stock valued at $2,680,000 after buying an additional 24,228 shares in the last quarter. DnB Asset Management AS raised its stake in shares of Boston Scientific Corporation by 12.3% in the first quarter. DnB Asset Management AS now owns 137,750 shares of the medical equipment provider’s stock valued at $3,426,000 after buying an additional 15,100 shares in the last quarter. Private Wealth Partners LLC raised its stake in shares of Boston Scientific Corporation by 3.4% in the first quarter. Private Wealth Partners LLC now owns 207,266 shares of the medical equipment provider’s stock valued at $5,155,000 after buying an additional 6,796 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Boston Scientific Corporation by 2.3% in the first quarter. Bank of Montreal Can now owns 511,136 shares of the medical equipment provider’s stock valued at $12,711,000 after buying an additional 11,611 shares in the last quarter. Institutional investors and hedge funds own 92.08% of the company’s stock.

Shares of Boston Scientific Corporation (BSX) opened at 26.41 on Friday. The firm has a 50-day moving average price of $27.34 and a 200-day moving average price of $26.04. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51. The company has a market capitalization of $36.24 billion, a PE ratio of 47.25 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the company earned $0.27 EPS. The company’s revenue was up 6.2% on a year-over-year basis. On average, equities research analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “BTIM Corp. Takes Position in Boston Scientific Corporation (BSX)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.com-unik.info/2017/08/12/btim-corp-takes-position-in-boston-scientific-corporation-bsx-updated-updated.html.

Several equities research analysts recently weighed in on BSX shares. Needham & Company LLC boosted their target price on Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 22nd. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Goldman Sachs Group, Inc. (The) started coverage on Boston Scientific Corporation in a report on Tuesday, May 16th. They issued a “neutral” rating and a $28.00 target price for the company. Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, BidaskClub lowered Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $30.06.

In other news, SVP David A. Pierce sold 2,972 shares of Boston Scientific Corporation stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $27.70, for a total value of $82,324.40. Following the transaction, the senior vice president now owns 28,572 shares in the company, valued at approximately $791,444.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific Corporation stock in a transaction on Thursday, June 29th. The shares were sold at an average price of $28.02, for a total value of $434,310.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 236,489 shares of company stock worth $6,440,888. Corporate insiders own 0.74% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit